Open AccessNotch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
Author(s) -
Nitin Roper,
Moises J. Velez,
Alberto Chiappori,
Yoo Sun Kim,
Jun S. Wei,
Sivasish Sindiri,
Nobuyuki Takahashi,
Deborah Mulford,
Suresh Kumar,
Kris Ylaya,
Christopher Trindade,
Irena Manukyan,
AnnaLeigh Brown,
Jane B. Trepel,
Jungmin Lee,
Stephen M. Hewitt,
Javed Khan,
Anish Thomas
Publication year - 2021
Publication title -
nature communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.559
H-Index - 365
ISSN - 2041-1723
DOI - 10.1038/s41467-021-24164-y
Subject(s) - notch signaling pathway , immune checkpoint , cancer research , blockade , immune system , signal transduction , pd l1 , phenotype , cell , lung cancer , t cell , biology , immunotherapy , oncology , medicine , immunology , receptor , gene , microbiology and biotechnology , genetics
Immune checkpoint blockade (ICB) benefits only a small subset of patients with small cell lung cancer (SCLC), yet the mechanisms driving benefit are poorly understood. To identify predictors of clinical benefit to ICB, we performed immunogenomic profiling of tumor samples from patients with relapsed SCLC. Tumors of patients who derive clinical benefit from ICB exhibit cytotoxic T-cell infiltration, high expression of antigen processing and presentation machinery (APM) genes, and low neuroendocrine (NE) differentiation. However, elevated Notch signaling, which positively correlates with low NE differentiation, most significantly predicts clinical benefit to ICB. Activation of Notch signaling in a NE human SCLC cell line induces a low NE phenotype, marked by increased expression of APM genes, demonstrating a mechanistic link between Notch activation, low NE differentiation and increased intrinsic tumor immunity. Our findings suggest Notch signaling as a determinant of response to ICB in SCLC.